Current role
Carolyn Ng, Ph.D.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Carolyn Ng, Ph.D.
Bicara Therapeutics Inc. reported in an 8-K filed July 28, 2026 that Carolyn Ng, Ph.D. was appointed member of the Nominating and Corporate Governance Committee, effective July 28, 2026.
“Effective as of the Appointment Date, the Board appointed (i) Dr. Bender to serve as a member of the Audit Committee of the Board (the “Audit Committee”), replacing Carolyn Ng, Ph.D., (ii) Ms. Oliger and Dr. Ng to serve as a members of the Nominating and Corporate Governance Committee, replacing Ms. Mazumdar-Shaw and Jake Simson, Ph.D., and (iii) Dr. Bender, Ms. Oliger and Kate Haviland to serve as members of the newly formed Launch Readiness Committee of the Board (the “Launch Readiness Committee”), with Ms. Haviland as chair of the Launch Readiness Committee, each until their respective successors are elected and qualified, or until their earlier death, resignation or removal, or until otherwise determined by the Board.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Bicara Therapeutics Inc. (BCAX)
SEC 8-K
Current2026-07-28–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Bicara Therapeutics Inc.
Other people whose current roles at this company are on record from its filings.
- Claire Mazumdar CEO
- Ivan Hyep CFO, Board Member
- Carolyn Ng Board Member
- Christopher Bowden Board Member
- Christy Oliger Board Member
- David Raben Board Member
- Jeremy Bender, Ph.D. Board Member
- Lara Meisner Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.